GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alto Neuroscience Inc (NYSE:ANRO) » Definitions » Total Payout Yield %

Alto Neuroscience (Alto Neuroscience) Total Payout Yield % : -39.61 (As of May. 26, 2024)


View and export this data going back to 2024. Start your Free Trial

What is Alto Neuroscience Total Payout Yield %?

Total Payout Yield % is the percent a company has paid to its shareholders through net repurchases of shares and dividends based on its Market Cap. It is a measure of shareholder return.

Alto Neuroscience's current Total Payout Yield % is -39.61%.


Alto Neuroscience Total Payout Yield % Historical Data

The historical data trend for Alto Neuroscience's Total Payout Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alto Neuroscience Total Payout Yield % Chart

Alto Neuroscience Annual Data
Trend Dec21 Dec22 Dec23
Total Payout Yield %
- - -

Alto Neuroscience Quarterly Data
Dec21 Sep22 Dec22 Mar23 Sep23 Dec23 Mar24
Total Payout Yield % Get a 7-Day Free Trial - - - - -133.36

Competitive Comparison of Alto Neuroscience's Total Payout Yield %

For the Biotechnology subindustry, Alto Neuroscience's Total Payout Yield %, along with its competitors' market caps and Total Payout Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alto Neuroscience's Total Payout Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alto Neuroscience's Total Payout Yield % distribution charts can be found below:

* The bar in red indicates where Alto Neuroscience's Total Payout Yield % falls into.



Alto Neuroscience Total Payout Yield % Calculation

Total Payout Yield % is a measure of shareholder return.

Alto Neuroscience's Total Payout Yield % for the fiscal year that ended in Dec. 2023 is calculated as

Total Payout Yield %=- (Repurchase of Stock + Issuance of Stock + Cash Flow for Dividends) / Market Cap
=- (0 + 0.181 + 0) / 0
=N/A%

Alto Neuroscience's annualized Total Payout Yield % for the quarter that ended in Mar. 2024 is calculated as

Total Payout Yield %=- (Repurchase of Stock + Issuance of Stock + Cash Flow for Dividends) * Annualized Factor / Market Cap
=- (0 + 137.579 + 0) * 4 / 412.6694
=-133.36%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Alto Neuroscience Total Payout Yield % Explanation

Similar to Dividend Yield, Total Payout Yield % is a measurement of shareholder return. Dividends is not the only way that companies are able to distribute their excess cash back to the shareholders. The other way to distribute the cash is a stock repurchase. The stock repurchase buys back the company's own shares from the marketplace. This results in a reduced number of oustanding shares, making each share worth a greater percentage of the corporation.


Alto Neuroscience Total Payout Yield % Related Terms

Thank you for viewing the detailed overview of Alto Neuroscience's Total Payout Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Alto Neuroscience (Alto Neuroscience) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
Website
Alto Neuroscience Inc is a clinical stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individuals' neurobiology to develop personalized and highly effective treatment options. the company currently consists of five clinical-stage assets initially targeting major depressive disorder and schizophrenia populations as identified by independent brain-based biomarkers.

Alto Neuroscience (Alto Neuroscience) Headlines

From GuruFocus